Abstract
Schizophrenia is a chronic and debilitating mental health condition that significantly impacts quality of life and can shorten patients’ lifetime by decades. It is characterized by symptoms including hallucinations and delusions, apathy, and cognitive impairment, and people with schizophrenia also experience many somatic comorbidities, such as metabolic disturbances, infectious diseases, cardiovascular issues, and respiratory illnesses. For decades, treatment for schizophrenia has focused on antipsychotics (APs) that reduce excess dopamine signaling to the associative striatum, which also blocks dopamine signaling in the dorsal striatum, creating movement disorders. Second-generation APs have a lower propensity to cause drug-induced movement disorders than first-generation APs. Nonetheless, only 1 out of 3 patients respond to any of the available APs; moreover, negative and cognitive symptoms tend to persist, while side effects and long-term risks can contribute to poor outcomes. However, there are new understandings in how to reduce dopamine release both presynaptically and selectively in circuits governing psychotic symptoms. These mechanisms offer a different treatment approach for patients with schizophrenia.
Continue Reading...
Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
References (22)
- Correll CU, Solmi M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248–271. PubMed CrossRef
- Faden J, Citrome L. Schizophrenia: one name, many different manifestations. Med Clin North Am. 2023;107(1):61–72. PubMed CrossRef
- De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders, I: prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52–77. PubMed CrossRef
- McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci. 2019;42(3):205–220. PubMed CrossRef
- Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectr. 2018;23(3):187–191. PubMed CrossRef
- Ito H, Takano H, Arakawa R, et al. Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA. PLoS One. 2012;7(9):e46488. PubMed CrossRef
- Correll CU, Abi-Dargham A, Howes O. Emerging treatments in schizophrenia. J Clin Psychiatry. 2022;83(1):SU21024IP1. PubMed CrossRef
- Samara MT, Nikolakopoulou A, Salanti G, et al. How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? an analysis based on individual patient data from randomized controlled trials. Schizophr Bull. 2019;45(3):639–646. PubMed CrossRef
- Citrome L. Vive la révolution! a paradigm shift in the pharmacological treatment of schizophrenia. Curr Med Res Opin. 2023;39(3):473–474. PubMed CrossRef
- Yohn SE, Weiden PJ, Felder CC, et al. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. Trends Pharmacol Sci. 2022;43(12):1098–1112. PubMed CrossRef
- Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165(8):1033–1039. PubMed CrossRef
- Breier A, Brannan SK, Paul SM, et al. Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results. Psychopharmacology (Berl). 2023;240(5):1191–1198. PubMed CrossRef
- Krystal JH, Kane JM, Correll CU, et al. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. 2022;400(10369):2210–2220. PubMed CrossRef
- Berry MD, Gainetdinov RR, Hoener MC, et al. Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges. Pharmacol Ther. 2017;180:161–180. PubMed CrossRef
- Dedic N, Dworak H, Zeni C, et al. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. Int J Mol Sci. 2021;22(24):13185. PubMed CrossRef
- Brannan SK, Sawchak S, Miller AC, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384(8):717–726. PubMed CrossRef
- Gallagher A. Karuna Therapeutics announces positive results from phase 3 EMERGENT-3 trial of KarXT in schizophrenia. Pharmacy Times. Published March 20, 2023. Accessed July 11, 2023. https://www.pharmacytimes.com/view/schizophrenia-treatment-karxt-meets-primary-endpoint-in-phase-3-trial
- Correll CU, Angelov AS, Brannan SK. Safety and Efficacy of KarXT (Xanomeline–Trospium) in Patients With Schizophrenia: Results From a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial (EMERGENT-2). Poster P.0193 presented at: 35th ECNP Congress; October 15–18, 2022; Vienna, Austria.
- Krystal JH, Kane JM, Correll CU, et al. CVL-231 as a Novel Positive Allosteric Modulator Targeting M4 Muscarinic Receptors: Results From a Phase 1b Trial in Patients With Schizophrenia. Presented at: 2022 Hybrid Congress of the Schizophrenia International Research Society; April 6, 2022; Florence, Italy. https://investors.cerevel.com/static-files/d8c8d2c7-3689-4be9-978a-c6b5a331be4a
- A Trial of 10 and 30 Mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia. ClinicalTrials.gov. Accessed July 11, 2023. https://classic.clinicaltrials.gov/ct2/show/NCT05227690
- Koblan KS, Kent J, Hopkins SC, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382(16):1497–1506. PubMed CrossRef
- Correll CU, Koblan KS, Hopkins SC, et al. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophr. 2021;7(1):63. PubMed CrossRef
Advertisement
GAM ID: sidebar-top